The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt, MD, University Medical Center Freiburg, Freiburg, Germany, shares her thoughts on the importance of bringing CAR-T cells into earlier lines of therapy in multiple myeloma, following the recent expanded approval of ciltacabtagene autoleucel (cilta-cel) by the FDA. Dr Engelhardt highlights that this is valuable for triple-class exposed patients, which remain a challenging population to treat. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
